MIRA Pharmaceuticals, Inc. (MIRA) today announced the pricing of its initial public offering of 1,275,000 shares of common stock at an initial public offering price of
The Company has granted the underwriter a 45-day option to purchase up to 191,250 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.
The offering is expected to close on
In connection with the offering, the Company has received approval to have the shares of its common stock listed on the Nasdaq Capital Market, with the shares expected to begin trading on
The Company expects to use the net proceeds from the offering to advance its clinical development programs and for working capital and general corporate purposes.
Kingswood Investments, division of Kingswood Capital Partners, LLC is acting as sole bookrunner for the offering.
A registration statement on Form S-1 (File No. 333-273024) relating to the securities was filed with the Securities and Exchange Commission ("SEC") and was declared effective by the SEC on